Finól (Finol) Filmuhúðuð tafla 5 mg Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

finól (finol) filmuhúðuð tafla 5 mg

actavis group ptc ehf. - finasteridum inn - filmuhúðuð tafla - 5 mg

Maxitrol Augndropar, dreifa Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

maxitrol augndropar, dreifa

novartis healthcare a/s - neomycinum súlfat; polymyxinum b súlfat; dexamethasonum fosfat - augndropar, dreifa

Piperacillin/Tazobactam WH Innrennslisstofn, lausn 4 g/0,5 g Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

piperacillin/tazobactam wh innrennslisstofn, lausn 4 g/0,5 g

williams & halls ehf. - piperacillinum natríum; tazobactamum natríum - innrennslisstofn, lausn - 4 g/0,5 g

Sabrilex Filmuhúðuð tafla 500 mg Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

sabrilex filmuhúðuð tafla 500 mg

sanofi-aventis norge as - vigabatrinum inn - filmuhúðuð tafla - 500 mg

Mhyosphere PCV ID Euroopa Liit - islandi - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svín - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Clopidogrel/Acetylsalicylic acid Teva Euroopa Liit - islandi - EMA (European Medicines Agency)

clopidogrel/acetylsalicylic acid teva

teva pharma b.v. - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - sturtu - eftir að/asetýlsalisýlsýru mg er ætlað til að fyrirbyggja atherothrombotic atburðum í fullorðinn sjúklinga þegar þú tekur bæði eftir og asetýlsalisýlsýru (asa). eftir að/asetýlsalisýlsýru mg er fastur‑skammt samsetning lyf fyrir áframhaldandi meðferð í:ekki l hækkun bráð kransæðastíflu (óstöðug hálsbólgu eða ekki q‑bylgja kransæðastíflu) þar á meðal sjúklinga gangast undir stoðneti staðsetningar eftir stungið kransæðastíflu interventionst hækkun, bráð myndun stíflufleygs í læknisfræðilega sjúklingum rétt fyrir segaleysandi meðferð.

Constella Euroopa Liit - islandi - EMA (European Medicines Agency)

constella

abbvie deutschland gmbh & co. kg - línaklótíð - ertanlegt þarmasvepp - lyf við hægðatregðu - constella er ætlað til meðferðar við meðhöndlun á meðallagi til alvarlega einkennum í þarmi með hægðatregðu (ibs-c) hjá fullorðnum.

Cystadane Euroopa Liit - islandi - EMA (European Medicines Agency)

cystadane

recordati rare diseases - betaine vatnsfrítt - homocystinuria - Önnur meltingarvegi og efnaskipti vörur, - adjunctive treatment of homocystinuria, involving deficiencies or defects in:cystathionine beta-synthase (cbs);5,10-methylene-tetrahydrofolate reductase (mthfr);cobalamin cofactor metabolism (cbl). cystadane should be used as supplement to other therapies such as vitamin b6 (pyridoxine), vitamin b12 (cobalamin), folate and a specific diet.